Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Infectious Disease · Human Immunodeficiency Virus Infection

Understanding HIV and Your Health

At a Glance

HIV is a manageable chronic condition when treated with antiretroviral therapy (ART). Starting ART early suppresses the virus, supports immune recovery, prevents progression to AIDS, and helps most people live nearly as long as those without HIV.

Receiving an HIV diagnosis can feel overwhelming, sparking a range of intense emotions from shock to fear. It is important to know that these feelings are a natural response to significant medical news. However, the medical landscape of HIV has been completely transformed. What was once an acute crisis is now a highly treatable and manageable chronic condition [1]. With modern Antiretroviral Therapy (ART)—medications that stop the virus from making copies of itself—most people living with HIV can expect a life expectancy that is near normal [2][3].

How HIV Interacts with Your Body

HIV is a retrovirus, a type of virus that works by inserting its own genetic code into your body’s cells [4]. Its primary target is the CD4+ T cell, often called a “helper” cell because it plays a role coordinating the defense against infections [5].

The virus enters these cells by binding to their surface and “fusing” with them. Once inside, it converts its viral RNA into DNA and integrates that DNA directly into your cell’s genetic code [4][6]. From there, the virus can force the cell to churn out thousands of new viral copies, eventually exhausting and destroying the host cell [7].

The Typical Stages of Untreated HIV

If left untreated, HIV typically moves through three distinct phases. Modern treatment is designed to stop this progression entirely. It is important to know that many people have no obvious symptoms during these phases, and your doctor cannot date the infection based solely on lab results.

  1. Acute Infection: This occurs within the first few weeks after exposure. The virus multiplies rapidly, and many people experience flu-like symptoms (though it is often asymptomatic). During this phase, the amount of virus in the blood (viral load) is very high, and there is an initial sharp drop in CD4 cells, particularly in the lining of the gut [8][9].
  2. Chronic Infection / Clinical Latency: After the initial burst, the virus settles into a slower but persistent phase. You may feel completely healthy for years, but the virus is still active at low levels, causing gradual immune damage and chronic inflammation [9][10].
  3. Advanced HIV (AIDS): If the immune system is severely damaged and the CD4 count falls below 200 cells/mm³ (or CD4 percentage below 14%) or an AIDS-defining illness occurs, the condition is classified as AIDS (Acquired Immunodeficiency Syndrome) [11]. At this stage, the body struggles to fight off “opportunistic infections” that a healthy immune system would easily handle [12].

Why Current Treatment is So Effective

The goal of Antiretroviral Therapy (ART) is to achieve viral suppression, where the amount of virus in your blood is so low that standard tests cannot detect it (often called being “undetectable”) [1].

Current medical guidelines recommend starting ART as soon as possible after diagnosis, regardless of your CD4 count [1]. Research like the START trial has proven that starting treatment early—even when you feel perfectly fine—significantly reduces the risk of serious AIDS-related illnesses and non-AIDS-related illness and death [13][14]. Early treatment allows your CD4 cells to recover and helps calm the systemic inflammation caused by the virus [15][16].

The Challenge of the “Latent Reservoir”

You may wonder why HIV requires daily medication rather than a one-time cure. This is due to the latent viral reservoir. Almost immediately after infection, the virus hides in “resting” immune cells where it remains inactive or “latent” [8][17].

Because these cells aren’t actively producing new virus, ART cannot eliminate them. If ART is stopped, the virus in this reservoir can “wake up” and begin multiplying again [18][19]. While scientists are investigating strategies to flush out this reservoir, current care focuses on using ART to keep the virus suppressed and inactive, allowing you to live a long, healthy life [20][21].

Feature Without Treatment With Modern ART
CD4 Count Progressively declines [11] Usually increases or stabilizes [15]
Viral Load High and fluctuates Undetectable (Suppressed) [1]
Progression Likely leads to AIDS [12] Prevents progression [13]
Life Expectancy Significantly shortened Near normal for most people [2]

Modern HIV care is about more than just surviving; it is about thriving. By starting treatment early and staying consistent, you take control of the virus and protect your long-term health [13].

Common questions in this guide

What does HIV do to the immune system?
HIV targets CD4 helper cells, which coordinate the body's defense against infections. Without treatment, the virus can reduce these cells and weaken immune protection. Antiretroviral therapy blocks the virus from making more copies and helps protect immune function.
What are the stages of HIV if it is not treated?
Untreated HIV usually progresses through acute infection, chronic infection or clinical latency, and advanced HIV known as AIDS. Early infection may cause flu-like symptoms or no symptoms, while the chronic phase can last for years despite ongoing immune damage. Antiretroviral therapy can stop this progression.
What do my CD4 count and viral load mean?
The CD4 count estimates the number of helper immune cells in your blood, while the viral load measures how much HIV is present. Effective ART usually lowers the viral load to an undetectable level and allows the CD4 count to recover or remain stable. Your clinician interprets both results together.
How soon should I start HIV treatment after diagnosis?
Current guidance recommends starting antiretroviral therapy as soon as possible after an HIV diagnosis, regardless of CD4 count. Early treatment lowers the risk of serious AIDS-related and other illnesses, supports CD4 recovery, and reduces inflammation caused by the virus.
Does an undetectable viral load mean that HIV is cured?
No. ART can reduce HIV in the blood to a level standard tests cannot detect, but some virus can remain hidden in resting immune cells. If treatment is stopped, this latent reservoir can become active and the virus can multiply again, so medication changes should be discussed with an HIV clinician.
What tests might I need before starting ART?
CD4 and viral load testing help show the current state of your immune system and the amount of virus in your blood. Resistance testing and hepatitis screening may also be needed to help your clinician finalize the safest treatment plan.
What is the outlook for someone living with HIV today?
With early and consistent ART, most people living with HIV can expect a near-normal life expectancy. Treatment usually suppresses the virus, prevents progression to AIDS, and helps CD4 cells recover or remain stable.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my current CD4 count and viral load, and what do these numbers tell us about my immune system today?
  2. 2.Based on my labs, do I have any signs of advanced immune damage, or am I in a stable stage?
  3. 3.What are the specific goals for my viral load once I start ART, and how long does it usually take to reach 'undetectable' status?
  4. 4.What lifestyle changes can I make to protect my long-term heart and kidney health?
  5. 5.Are there any other tests, like resistance testing or hepatitis screenings, that we need to complete before finalizing my treatment plan?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Same-day and rapid initiation of antiretroviral therapy in people living with HIV in Asia. How far have we come?

    Hung CC, Phanuphak N, Wong CS, et al.

    HIV medicine 2022; (23 Suppl 4()):3-14 doi:10.1111/hiv.13410.

    PMID: 36254390
  2. 2

    Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies.

    The lancet. HIV 2017; (4(8)):e349-e356 doi:10.1016/S2352-3018(17)30066-8.

    PMID: 28501495
  3. 3

    Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016.

    Marcus JL, Leyden WA, Alexeeff SE, et al.

    JAMA network open 2020; (3(6)):e207954 doi:10.1001/jamanetworkopen.2020.7954.

    PMID: 32539152
  4. 4

    Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection.

    Hou P, Chen S, Wang S, et al.

    Scientific reports 2015; (5()):15577 doi:10.1038/srep15577.

    PMID: 26481100
  5. 5

    The impact of HIV-1 Nef on CD4+ T cells.

    Yaseen MM, Abuharfeil NM, Darmani H

    Critical reviews in biochemistry and molecular biology 2026; (61(1-3)):24-54 doi:10.1080/10409238.2025.2599773.

    PMID: 41770614
  6. 6

    The multifaceted nature of HIV latency.

    Dufour C, Gantner P, Fromentin R, Chomont N

    The Journal of clinical investigation 2020; (130(7)):3381-3390.

    PMID: 32609095
  7. 7

    The role of pyroptosis during HIV infection.

    Yaseen MM, Abuharfeil NM, Darmani H, Shatnawi MN

    Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2026; (75(1)):12 doi:10.1007/s00011-025-02164-8.

    PMID: 41504820
  8. 8

    Kinetics of Early Innate Immune Activation during HIV-1 Infection of Humanized Mice.

    Skelton JK, Ortega-Prieto AM, Kaye S, et al.

    Journal of virology 2019; (93(11)) doi:10.1128/JVI.02123-18.

    PMID: 30867315
  9. 9

    The Hitchhiker Guide to CD4+ T-Cell Depletion in Lentiviral Infection. A Critical Review of the Dynamics of the CD4+ T Cells in SIV and HIV Infection.

    Le Hingrat Q, Sereti I, Landay AL, et al.

    Frontiers in immunology 2021; (12()):695674 doi:10.3389/fimmu.2021.695674.

    PMID: 34367156
  10. 10

    Cytokines and T-Cell Homeostasis in HIV Infection.

    Freeman ML, Shive CL, Nguyen TP, et al.

    The Journal of infectious diseases 2016; (214 Suppl 2()):S51-7 doi:10.1093/infdis/jiw287.

    PMID: 27625431
  11. 11

    Immune Control of HIV.

    Balasubramaniam M, Pandhare J, Dash C

    Journal of life sciences (Westlake Village, Calif.) 2019; (1(1)):4-37.

    PMID: 31468033
  12. 12

    Pneumocystis Pneumonia-Is it Still a Threat Among People With Human Immunodeficiency Virus (HIV)? A Danish HIV Cohort Study.

    Møller AK, Schnoor SB, Petersen I, et al.

    Open forum infectious diseases 2025; (12(6)):ofaf289 doi:10.1093/ofid/ofaf289.

    PMID: 40463830
  13. 13

    Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

    , Lundgren JD, Babiker AG, et al.

    The New England journal of medicine 2015; (373(9)):795-807 doi:10.1056/NEJMoa1506816.

    PMID: 26192873
  14. 14

    A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.

    , Danel C, Moh R, et al.

    The New England journal of medicine 2015; (373(9)):808-22 doi:10.1056/NEJMoa1507198.

    PMID: 26193126
  15. 15

    The benefit of immediate compared with deferred antiretroviral therapy on CD4+ cell count recovery in early HIV infection.

    Sharma S, Schlusser KE, de la Torre P, et al.

    AIDS (London, England) 2019; (33(8)):1335-1344 doi:10.1097/QAD.0000000000002219.

    PMID: 31157663
  16. 16

    Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection.

    Sereti I, Krebs SJ, Phanuphak N, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2017; (64(2)):124-131 doi:10.1093/cid/ciw683.

    PMID: 27737952
  17. 17

    Transcriptional Reprogramming during Effector-to-Memory Transition Renders CD4+ T Cells Permissive for Latent HIV-1 Infection.

    Shan L, Deng K, Gao H, et al.

    Immunity 2017; (47(4)):766-775.e3 doi:10.1016/j.immuni.2017.09.014.

    PMID: 29045905
  18. 18

    HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing.

    Yukl SA, Kaiser P, Kim P, et al.

    Science translational medicine 2018; (10(430)) doi:10.1126/scitranslmed.aap9927.

    PMID: 29491188
  19. 19

    Proviruses with identical sequences comprise a large fraction of the replication-competent HIV reservoir.

    Bui JK, Sobolewski MD, Keele BF, et al.

    PLoS pathogens 2017; (13(3)):e1006283 doi:10.1371/journal.ppat.1006283.

    PMID: 28328934
  20. 20

    Breaking the Silence: Regulation of HIV Transcription and Latency on the Road to a Cure.

    Duggan NN, Dragic T, Chanda SK, Pache L

    Viruses 2023; (15(12)) doi:10.3390/v15122435.

    PMID: 38140676
  21. 21

    Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies.

    Crooks AM, Bateson R, Cope AB, et al.

    The Journal of infectious diseases 2015; (212(9)):1361-5 doi:10.1093/infdis/jiv218.

    PMID: 25877550

This page is for informational purposes only and does not constitute medical advice. An HIV clinician can help interpret your CD4 count and viral load and choose the right ART plan for you.

Get notified when new evidence is published on HIV infectious disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.